Novocure's device shown to slow cancer progression in the brain in trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Novocure (NVCR) shares jump after trial meets primary endpoint
March 27, 2024 9:58 AM EDTShares of Novocure (NASDAQ: NVCR) jumped Wednesday after the company reported before the open that its phase 3 METIS clinical trial met its primary endpoint.
The company's lung cancer demonstrated the slowing in the progression of cancer to the brain in... More
